Traws Pharma Q4 Earnings Call Highlights
by Renee Jackson · The Cerbat GemTraws Pharma (NASDAQ:TRAW) used its full-year 2025 results call to highlight progress on its lead influenza candidate, Tivoxavir marboxil, and to outline how a newly announced private financing is expected to fund upcoming clinical milestones. Chief Executive Officer Dr. Iain D. Dukes and Chief Financial Officer Charles Parker also discussed the company’s cash position and key regulatory developments, including an FDA clinical hold tied to toxicology questions.
Financing aims to fund summer influenza challenge study
Dukes said the company announced a private financing “of $60 million” supported by “new and existing healthcare-focused investors.” He said the proceeds are intended to position the company to advance its influenza program “through the human challenge study this summer,” while also providing access to additional capital as milestones are achieved.
Parker provided details on the structure, saying the private placement includes “$10 million upfront” and three warrants that together could provide up to $60 million in potential gross proceeds. The warrants include:
- Series A milestone-based warrant: aggregate exercise price of $10 million, exercisable upon MHRA approval to conduct the challenge trial.
- Series B milestone-based warrant: aggregate exercise price of $10 million, exercisable following both shareholder approval and the announcement of challenge trial data.
- Series C common warrant: a three-year warrant that could provide $30 million if fully exercised following shareholder approval.
Parker added that, based on current plans, management believes the company’s current cash balance, “including net proceeds from the offering in milestone-based warrants, if fully exercised,” is sufficient to support planned expenses into “Q1 2027.”
Tivoxavir positioned as once-monthly prophylactic influenza antiviral
Dukes focused much of his prepared remarks on Tivoxavir marboxil, which he described as a “next generation investigational influenza antiviral” targeting the “highly conserved viral enzyme cap-dependent endonuclease.” The company is prioritizing Tivoxavir as a prophylactic agent for influenza prevention, which Dukes characterized as a “multi-billion-dollar opportunity” spanning prophylactic and therapeutic use, with potential relevance to government stockpiling and pandemic preparedness.
Dukes said Traws envisions Tivoxavir’s potential use in two settings: monthly prophylaxis during flu season and as part of a national stockpile for pandemic preparedness. He said the company believes Tivoxavir could be “well-positioned to become a best-in-class once monthly oral prophylactic agent” with potential applicability to pandemic strains “including H5N1 bird flu.”
In support of the company’s development thesis, Dukes cited three pillars:
- Previously reported preclinical studies showing “robust antiviral activity against a wide range of influenza strains,” including influenza A and B.
- Preclinical data reported last year indicating a “single dose” provided protection against lethal bird flu challenge in three species, including reductions in lung virus burden and pathology in non-human primates.
- Phase 1 data showing the first-generation powder and capsule formulation maintained plasma levels “well above the EC90 for over three weeks” with “good overall safety.”
He also noted development of a “next generation compressed tablet formulation” with an optimized pharmacokinetic profile. Preclinical data, he said, showed a “30% increase in exposure” with the new tablet, which the company believes could provide “28-day coverage against influenza.”
Near-term clinical plans: bridging study and UK human challenge trial
Traws is conducting a phase 1 “bridge study in Australia” to confirm extended exposure observed in preclinical studies, Dukes said. He added that positive bridging data will be shared with the UK Medicines and Healthcare products Regulatory Agency (MHRA) along with initial submissions already filed.
The company’s next targeted step is a Phase 2a “seasonal flu prophylaxis challenge trial,” which Dukes said will be conducted at hVIVO in the UK and is expected to start “in June,” with initiation planned this summer pending MHRA approval. Dukes described positive results showing protection from viral infection as a “landmark proof of concept” for Tivoxavir’s prophylactic value proposition.
During the Q&A, Cantor Fitzgerald analyst Alethia Young asked about the potential for MHRA delays given the toxicology questions raised by the FDA. Dukes said he could not predict the MHRA outcome, noting the package is under a “30-day clock” for review. He also pointed to different outcomes across regulators, stating that Australia’s regulatory process had allowed Traws to proceed with studies based on the same toxicology data that led to the FDA’s hold.
FDA clinical hold tied to toxicology package; company plans additional assays
On the U.S. regulatory front, Dukes said the company submitted an Investigational New Drug (IND) application in January in support of formal consideration by the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in the U.S. strategic stockpile. However, he said the FDA has placed the IND on clinical hold due to “concerns with the toxicology data package.” Dukes said Traws is engaging with the FDA to address concerns and aims to advance the program in the U.S. in “late 2026.”
Asked specifically about mutagenicity risk and the potential need for new experiments, Dukes said the structural similarity to Xofluza was relevant and asserted that Tivoxavir “has a clean mutagenicity label,” including being “negative in Ames,” adding that it has shown no mutagenic potential since approval. He said Traws plans to repeat some assays, submit new assays, and use Xofluza “as an additional control” in submissions to the FDA. Dukes said management has confidence that the in vitro data suggesting mutagenic risk may be explainable through other mechanisms.
Dukes also addressed potential dosing flexibility. While the company is prioritizing once-monthly prophylaxis, he said Traws would evaluate challenge trial results across timepoints—“1 week, 2 week, 3 week, as well as 4 weeks”—and decide on dosing frequency for a future Phase 2b/3 program based on observed protection.
Financial results: cash declined year-over-year; net income reported in 2025
Parker summarized the company’s full-year results for the period ended Dec. 31, 2025. Traws reported cash, cash equivalents, and short-term investments of “approximately $3.8 million,” down from $21.3 million at the end of 2024.
Revenue for 2025 was “$2.8 million,” compared with $226,000 in 2024. Parker attributed the increase primarily to “$0.7 million in deferred revenue recognized as revenue in the second quarter” tied to the mutual termination of a licensing agreement associated with a legacy oncology program in April 2025.
Research and development expense totaled “$12.1 million” in 2025 versus $12.8 million in 2024, with the decline driven by lower oncology-related expenses partially offset by higher virology program spending. General and administrative expense fell to “$8.5 million” from $12.3 million, primarily due to lower professional and consulting fees.
Traws reported net income of “$9.2 million,” or $0.83 per basic share and $0.82 per diluted share, compared with a net loss of $166.5 million in 2024.
In closing remarks, Dukes reiterated that the financing is intended to support the company’s planned seasonal influenza prophylaxis study and that Traws is focused on completing the bridging study and initiating the UK challenge trial during the summer.
About Traws Pharma (NASDAQ:TRAW)
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.